Sideroblastic Anemia 3

1. Disease Information

1.1 Definition and Clinical Overview

Sideroblastic anemia 3 (SIDBA3) is defined as an autosomal recessive hereditary sideroblastic anemia caused by pathogenic variants in GLRX5, a mitochondrial glutaredoxin required for Fe–S cluster assembly and maintenance of cellular iron homeostasis.[3][10][13] Sideroblastic anemias as a group are characterized by the presence of ringed sideroblasts in the bone marrow—erythroid precursors that harbor pathological iron-laden mitochondria arranged in a perinuclear ring—and by defective incorporation of iron into heme despite normal or increased body iron stores.[3][9] In the specific case of GLRX5-related SIDBA3, patients present with microcytic hypochromic anemia that is refractory to pyridoxine (vitamin B6) supplementation, in contrast to classic X-linked ALAS2-related pyridoxine-responsive sideroblastic anemia.[4][8][13] The anemia is accompanied by biochemical and radiologic evidence of systemic iron overload, most prominently in the liver, and clinical sequelae may include hepatopathy and type 2 diabetes, reflecting the toxic effects of chronic iron deposition in parenchymal organs.[4][13][14]

The initial human case of GLRX5 deficiency presenting as sideroblastic anemia was described in a middle-aged man with longstanding microcytic anemia and hepatic iron overload, whose cells revealed a defect in intron 1 splicing of GLRX5 leading to markedly reduced GLRX5 transcript levels and biochemical hallmarks of Fe–S cluster deficiency.[14] Subsequent studies, including detailed mechanistic work by Ye and colleagues, demonstrated that GLRX5 is essential for Fe–S cluster biogenesis in human cells and that its deficiency in erythroid precursors selectively impairs heme synthesis by interfering with the activity and translation of ALAS2 and ferrochelatase, the first and last enzymes of the mitochondrial heme biosynthetic pathway.[10][1] Orphanet and MalaCards now recognize “Adult-onset autosomal recessive sideroblastic anemia” due to GLRX5 as a distinct entity, emphasizing its adult onset, microcytic hypochromic anemia, liver iron overload, and resistance to pyridoxine therapy.[4][13] However, because only a few affected individuals have been reported, the full clinical spectrum and natural history of SIDBA3 remain incompletely defined.[11][13][14]

1.2 Nosology, Identifiers, and Disease Classification

In contemporary nosology, GLRX5-related sideroblastic anemia is catalogued under several overlapping identifiers that reflect its position within the broader category of hereditary sideroblastic anemias and rare hematologic disorders. OMIM assigns the phenotype “Anemia, sideroblastic, 3, pyridoxine-refractory” the entry number 616860 and links it to the GLRX5 gene (MIM 609588) located on chromosome 14q32.[3][13] The Mondo Disease Ontology term MONDO:0014804 corresponds to “sideroblastic anemia 3,” and this association is explicitly referenced in model organism resources such as PomBase, which notes the disease term MONDO:0014804 as “sideroblastic anemia 3.”[5] Orphanet describes “Adult-onset autosomal recessive sideroblastic anemia” due to a splice defect of GLRX5 and assigns this condition Orphanet ID 255132, characterizing it as “a very rare non-syndromic autosomal recessive pyridoxine-refractory sideroblastic anemia due to a splice defect of glutaredoxin-5 (GLRX5) described in a single patient with adult onset microcytic hypochromic anemia with liver iron overload and type 2 diabetes.”[4][13]

From an ICD perspective, hereditary sideroblastic anemias are grouped under ICD-10 code D64.0 (“Hereditary sideroblastic anaemia”), with secondary sideroblastic anemias assigned to D64.1 and D64.2 depending on underlying etiology.[9] Although ICD-10 does not distinguish specific genetic subtypes such as SIDBA3, the combination of hereditary sideroblastic anemia and autosomal recessive inheritance provides a reasonable coding approximation for GLRX5-related disease.[9][3] In terms of MeSH and SNOMED CT, sideroblastic anemia is represented by MeSH term C535397 and SNOMED CT code 48983004, with subtyping by gene increasingly captured in emerging ontologies rather than legacy clinical terminologies.[3][9] Within the broader classification of sideroblastic anemias, OMIM distinguishes five major hereditary forms: SIDBA1 (ALAS2, X-linked), SIDBA2 (SLC25A38, autosomal recessive), SIDBA3 (GLRX5, autosomal recessive), SIDBA4 (HSPA9, autosomal dominant), and SIDBA5 (HSCB, autosomal recessive), highlighting the genetic heterogeneity underlying similar hematologic phenotypes.[3]

1.3 Synonyms and Alternative Names

The literature and databases employ a range of synonyms for GLRX5-related sideroblastic anemia, reflecting different emphases on clinical features, inheritance, and molecular etiology. OMIM and MalaCards use the formal name “Anemia, sideroblastic, 3, pyridoxine-refractory” and the abbreviation SIDBA3, underscoring both its order in the series of hereditary sideroblastic anemias and its lack of response to pyridoxine supplementation.[3][13] Orphanet and NCBI’s Genetic Testing Registry refer to “Adult-onset autosomal recessive sideroblastic anemia” caused by GLRX5 splice defects, often appending the phrase “GLRX5-related sideroblastic anemia” or “GLRX5 deficiency” to highlight the molecular cause.[4][6][13] In clinical case reports, the condition has been described as “the human counterpart of zebrafish shiraz” to emphasize its resemblance to the severe anemia observed in the GLRX5-null zebrafish mutant shiraz, although this phrase is more metaphorical than taxonomically precise.[14]

Because GLRX5 mutations can also cause a distinct neurological metabolic disorder termed “variant non-ketotic hyperglycinemia” (variant NKH), some articles refer broadly to “GLRX5-associated disease” or “GLRX5 deficiency” without specifying the phenotype, making it important to distinguish the hematologic SIDBA3 entity from GLRX5-related NKH when interpreting the literature.[7][1] For the purposes of disease knowledge bases, the most precise synonyms are “GLRX5-related autosomal recessive sideroblastic anemia,” “Adult-onset autosomal recessive sideroblastic anemia due to GLRX5,” and “Anemia, sideroblastic, 3, pyridoxine-refractory (SIDBA3),” all of which convey the core clinical and genetic identity of the condition.[3][4][13]

1.4 Evidence Sources and Data Aggregation

The information available on SIDBA3 is derived predominantly from aggregated disease-level resources that synthesize data from individual case reports and mechanistic studies, rather than from large cohort studies or electronic health record (EHR)–based analyses. OMIM’s entry for SIDBA3 draws heavily on the original case report of GLRX5 deficiency in a middle-aged man with microcytic anemia and iron overload, as well as subsequent mechanistic work by Ye et al. and genetic studies identifying additional GLRX5 variants associated with sideroblastic anemia.[3][10][14][11] Orphanet’s description of adult-onset autosomal recessive sideroblastic anemia due to GLRX5 explicitly notes that the disease definition is based on a single reported patient, emphasizing the extremely limited clinical dataset.[4] MalaCards consolidates information from OMIM, Orphanet, PubMed, and other databases, listing GLRX5 as the sole gene with strong evidence for SIDBA3 and citing six key publications, including the JCI and Blood reports and later genetic studies.[13][10][14][11]

PanelApp submissions from Genomics England and the Genetic Testing Registry similarly rely on curated literature to designate GLRX5 as an autosomal recessive disease gene for “sideroblastic anemia 3” and “Adult-onset autosomal recessive sideroblastic anemia,” respectively.[2][6] Thus, while individual patient data underpin the original description of the disease, most publicly accessible information is mediated through expert-curated resources that aggregate and interpret these case reports and experimental studies. No large-scale epidemiologic, registry-based, or EHR mining studies have yet been published specifically on SIDBA3, and given the rarity of the condition, such datasets may be difficult to assemble.[4][13][14] This reliance on case-based and experimental evidence should be kept in mind when inferring the generalizability of phenotypic and prognostic statements about GLRX5-related sideroblastic anemia.

2. Etiology

2.1 Genetic Causal Factors: GLRX5 as the Primary Driver

The primary and, to date, only established causal factor for sideroblastic anemia 3 is biallelic germline mutation in the GLRX5 gene, which encodes glutaredoxin 5, a small mitochondrial protein involved in Fe–S cluster biogenesis.[3][10][14] GLRX5 belongs to the glutaredoxin family of thiol-disulfide oxidoreductases and participates in the transfer and repair of Fe–S clusters, acting within a conserved mitochondrial Fe–S assembly machinery that includes scaffold proteins and chaperones.[10][1] In the original human case described by Camaschella and colleagues, the patient carried a homozygous c.294A>G transition in GLRX5 that disrupted intron 1 splicing, drastically reducing GLRX5 mRNA and protein levels and leading to biochemical evidence of Fe–S cluster deficiency.[14] Functional studies showed reduced activities of Fe–S–dependent enzymes, altered IRP1/IRP2 regulation, and impaired heme synthesis, linking the genetic lesion directly to the hematologic phenotype.[14][10]

Ye et al. later confirmed that GLRX5 is essential for Fe–S cluster biosynthesis and iron homeostasis in human cells, using RNA interference to knock down GLRX5 in cultured cells and observing impaired Fe–S cluster formation, activation of IRP1 IRE-binding, increased IRP2 levels, cytosolic iron depletion, and mitochondrial iron overload.[10][12] They also demonstrated that GLRX5-deficient human erythroblasts exhibited selective impairment of heme biosynthesis and accumulation of mitochondrial iron, recapitulating key features of sideroblastic anemia at the cellular level.[10] More recently, Arias and colleagues reported two new GLRX5 mutations in patients with sideroblastic anemia, further consolidating GLRX5 as the causal gene for SIDBA3 and extending the allelic series beyond the original splice-site mutation.[11][13] Taken together, these human clinical and in vitro data establish GLRX5 loss-of-function variants as the definitive genetic etiology of sideroblastic anemia 3.[3][10][11][14]

2.2 Spectrum of Pathogenic GLRX5 Variants

The pathogenic variant spectrum in GLRX5 associated with sideroblastic anemia includes splice-site, missense, small in-frame deletion, and frameshift mutations, each predicted to impair GLRX5 protein function and Fe–S cluster biogenesis.[14][7][11][13] The c.294A>G splice-site mutation in intron 1 is the prototypical lesion described in the first human case; it disrupts normal splicing, leading to reduced GLRX5 mRNA and, consequently, reduced protein, with functional consequences consistent with a loss-of-function mechanism.[14] In the context of variant non-ketotic hyperglycinemia, several GLRX5 mutations have been reported that cause more severe, multisystem disease: Chiong et al., Wei et al., Baker et al., and Feng et al. describe homozygous or compound heterozygous mutations such as c.151_153delAAG (p.K51del), an in-frame deletion in exon 1, and c.82_83insGCGTGCGG (p.G28Gfs*25), an 8-bp insertion causing a frameshift and premature stop codon, as well as c.196C>T (p.Q66Ter), a nonsense variant truncating the protein.[7] These mutations abolish or profoundly disrupt GLRX5 function and are associated with severe neurological phenotypes, but they confirm that GLRX5 loss-of-function mutations can be pathogenic in humans.

MalaCards lists additional GLRX5 missense variants, including p.Lys101Gln and p.Leu148Ser, associated with sideroblastic anemia in at least one Chinese patient, although in that case heterozygous missense mutations were reported and the exact mechanism of disease (haploinsufficiency vs dominant-negative) remains to be fully elucidated.[13] Arias et al. (2023) reportedly identified two novel GLRX5 mutations causing sideroblastic anemia, though the specific nucleotide changes and functional data are not fully detailed in accessible summaries.[11][13] Collectively, these observations indicate that both canonical loss-of-function mutations (splice-site, nonsense, frameshift) and certain missense or in-frame deletions can be pathogenic when present in biallelic combination, provided they sufficiently impair GLRX5’s capacity to support Fe–S cluster assembly.[10][1][11][14] To date, all GLRX5 variants definitively linked to sideroblastic anemia are germline and affect the mitochondrial isoform of glutaredoxin 5, with no somatic mutations reported as causes of acquired sideroblastic anemia.[3][10][14]

2.3 Risk Factors: Genetic and Non-Genetic Considerations

The chief risk factor for developing SIDBA3 is inheriting two pathogenic GLRX5 alleles, either in a homozygous state or as compound heterozygotes, reflecting the autosomal recessive mode of inheritance.[2][3][4][13] Because pathogenic GLRX5 variants are extremely rare in the general population, as implied by Orphanet’s estimated prevalence of <1 per 1,000,000 for adult-onset autosomal recessive sideroblastic anemia and by the very small number of reported patients, the absolute risk for most individuals is negligible.[4][13] However, consanguinity or endogamy in populations where a founder GLRX5 mutation has arisen could increase the probability of biallelic inheritance, a pattern observed in other recessive sideroblastic anemias, though no specific GLRX5 founder mutation has yet been documented.[3][15] Heterozygous carriers of GLRX5 pathogenic variants are generally asymptomatic or may exhibit only mild laboratory abnormalities, reflecting the recessive nature of the disease.[14][11][13]

Non-genetic risk factors such as environmental exposures, toxins, medications, or nutritional deficiencies are not known to predispose specifically to GLRX5-related sideroblastic anemia, although they can cause acquired sideroblastic anemia through distinct mechanisms, such as direct inhibition of heme synthesis or mitochondrial toxicity.[9] Classic acquired causes include chronic alcohol use, lead poisoning, and certain drugs (e.g., isoniazid, linezolid), but these act independently of GLRX5 and are categorized separately as secondary sideroblastic anemias.[9] Nonetheless, in individuals with underlying GLRX5 mutations, such exposures could theoretically exacerbate anemia or iron overload by further impairing mitochondrial function or heme synthesis, although such gene–environment interactions have not been systematically documented.[9][13] Family history of sideroblastic anemia or unexplained microcytic anemia, especially in the context of iron overload and absence of common etiologies, should be considered a clinical cue to evaluate for hereditary forms including GLRX5-related disease.[3][14]

2.4 Protective Factors and Gene–Environment Interactions

No specific genetic protective factors or modifier alleles have been identified that reliably attenuate the severity of GLRX5-related sideroblastic anemia, in contrast to some other hereditary hematologic disorders where co-inherited variants can modulate phenotype (e.g., fetal hemoglobin modifiers in sickle cell disease).[3][11] It is conceivable that variation in genes involved in iron metabolism (such as HFE, TFRC, or ferroportin) or in the heme biosynthetic pathway could influence the clinical expression of GLRX5 deficiency by altering iron distribution or residual heme synthesis, but such hypotheses remain speculative in the absence of systematic studies.[10][14] Similarly, epigenetic regulation of GLRX5 expression or compensatory upregulation of alternative Fe–S assembly components could theoretically modulate disease severity, yet no empirical data are available for SIDBA3.[10][1]

From an environmental standpoint, avoidance of additional iron loading—through limiting unnecessary blood transfusions or iron supplementation—can be considered a protective strategy in patients already diagnosed with GLRX5-related sideroblastic anemia, as chronic iron excess exacerbates organ damage and metabolic complications.[14][13] In the index patient, anemia was worsened by repeated blood transfusions but partially ameliorated by iron chelation therapy, which redistributed iron from overloaded mitochondria to the cytosol and improved heme synthesis.[14] This observation suggests a gene–environment interaction in which therapeutic manipulation of iron distribution can modify the clinical course of GLRX5 deficiency. As summarized by Camaschella et al., “Iron chelation, redistributing iron to the cytosol, might relieve IRP2 excess, improving heme synthesis and anemia,” highlighting how environmental (therapeutic) interventions interact with the molecular consequences of GLRX5 mutations.[14] Beyond these considerations, no lifestyle or nutritional factors have been formally demonstrated to reduce the risk of developing SIDBA3 in genetically susceptible individuals, largely because the disease is so rare that prospective prevention studies are impractical.[4][13]

3. Phenotypes

3.1 Core Hematologic Phenotypes

The defining phenotype of GLRX5-related sideroblastic anemia is a chronic, microcytic hypochromic anemia, typically with adult onset, accompanied by bone marrow ringed sideroblasts and evidence of ineffective erythropoiesis.[4][13][14] Microcytic hypochromic anemia refers to red blood cells that are smaller than normal (low mean corpuscular volume) and paler due to reduced hemoglobin content (low mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration), reflecting impaired heme synthesis.[9] In the index GLRX5-deficient patient, anemia had been recognized in adulthood and was characterized by low hemoglobin, low MCV, and hypochromia, with erythroid hyperplasia evident in the bone marrow, consistent with compensatory expansion of erythroid precursors despite ineffective maturation.[14] The presence of ringed sideroblasts—erythroblasts with iron-laden mitochondria encircling the nucleus—confirms the diagnosis of sideroblastic anemia and reflects mitochondrial iron accumulation due to defective heme incorporation.[9][14] Interestingly, Camaschella et al. noted that the number of ringed sideroblasts in this patient was relatively low compared to other forms of sideroblastic anemia, suggesting subtle differences in marrow morphology associated with GLRX5 deficiency.[14]

This hematologic phenotype aligns with mechanistic studies in GLRX5-deficient human erythroblasts, which demonstrate impaired heme synthesis and mitochondrial iron overload, recapitulating microcytic hypochromic anemia and ring sideroblast formation at the cellular level.[10] Ye et al. reported that in GLRX5-deficient cells, Fe–S cluster biosynthesis was impaired, iron regulatory protein 1 (IRP1) IRE-binding activity was activated, and increased IRP2 levels were observed together with mitochondrial iron overload and cytosolic iron depletion.[10][12] These biochemical changes lead to decreased translation of ALAS2 and reduced activity of ferrochelatase, the terminal heme biosynthetic enzyme, manifesting clinically as microcytic hypochromic anemia.[1][10] Suggested HPO terms for these core hematologic phenotypes include “Microcytic anemia,” “Hypochromic anemia,” “Ring sideroblasts,” and “Erythroid hyperplasia,” all of which capture key features of GLRX5-related disease.

3.2 Iron Overload and Organ-Specific Manifestations

Beyond the anemia itself, GLRX5-related sideroblastic anemia is consistently associated with systemic iron overload, particularly affecting the liver, and can lead to metabolic complications such as type 2 diabetes.[4][13][14] Orphanet describes the GLRX5-related adult-onset autosomal recessive sideroblastic anemia as characterized by “adult onset microcytic hypochromic anemia with liver iron overload and type 2 diabetes,” indicating that hepatic iron deposition and diabetes were prominent features in the index patient.[4] In that case, serum iron and transferrin saturation were elevated, ferritin levels were high, and imaging or biopsy revealed hepatic iron excess, consistent with secondary hemochromatosis due to chronic ineffective erythropoiesis and repeated transfusions.[14] Camaschella et al. emphasized that anemia had been worsened by blood transfusions but partially reversed by iron chelation, underscoring the central role of iron overload in the pathophysiology and symptomatology of the disease.[14]

MalaCards similarly notes that SIDBA3 is “characterized by anemia in adulthood, systemic iron overload, and resistance to vitamin B6 treatment,” and that affected individuals may benefit clinically from iron chelation therapy.[13] The combination of microcytic hypochromic anemia and systemic iron overload is pathognomonic of hereditary sideroblastic anemias and reflects a mismatch between iron availability and its incorporation into heme, leading to iron accumulation in mitochondria and parenchymal organs.[3][9] Organ-specific consequences can include hepatic dysfunction, endocrinopathies such as diabetes (due to pancreatic iron deposition), and cardiac abnormalities, although detailed characterization of extra-hematologic phenotypes in GLRX5-related disease is limited by the small number of reported cases.[4][13][14] Potential HPO terms capturing these features include “Hepatic iron overload,” “Hyperferritinemia,” “Elevated transferrin saturation,” and “Type 2 diabetes mellitus.”

3.3 Clinical Course, Severity, and Quality-of-Life Impact

The clinical course of GLRX5-related sideroblastic anemia, as currently understood, is chronic and slowly progressive, with anemia manifesting in adulthood and iron overload accumulating over years of ineffective erythropoiesis and transfusional therapy.[4][13][14] In the index patient, anemia had been present for many years before the molecular diagnosis of GLRX5 deficiency was established, and iron overload had progressed to the point of causing liver dysfunction and diabetes.[14] Orphanet’s disease description emphasizes adult onset and non-syndromic presentation, meaning that aside from anemia and iron-related complications, no major congenital malformations or neurodevelopmental anomalies were noted in the adult-onset GLRX5-related sideroblastic anemia case.[4] The severity of anemia appears moderate to severe, requiring transfusions in some instances, although iron chelation can improve hemoglobin levels by redistributing iron and partially restoring heme synthesis.[14][13]

Quality-of-life impact in GLRX5-related SIDBA3 can be inferred from the general consequences of chronic anemia and iron overload: fatigue, reduced exercise tolerance, and diminished functional capacity due to low hemoglobin, combined with potential complications of iron-induced organ damage such as liver disease, diabetes, and cardiovascular issues.[4][13][14] MalaCards notes that iron chelation therapy may be beneficial, suggesting that effective management of iron overload can improve symptoms and functional status.[13] However, detailed patient-reported outcomes using standardized instruments such as SF-36 or EQ-5D have not been published for this extremely rare condition.[4][13] Overall, GLRX5-related sideroblastic anemia is best conceptualized as a chronic, lifelong disorder with significant morbidity due to anemia and iron overload, but with potential for clinical improvement if iron is carefully managed and transfusion requirements reduced.[14][13]

3.4 GLRX5-Related Variant Non-Ketotic Hyperglycinemia: A Distinct Phenotypic Spectrum

It is important to acknowledge that GLRX5 mutations can also cause a distinct neurological metabolic disorder known as variant non-ketotic hyperglycinemia (variant NKH), which shares the same causal gene but presents with a very different phenotype dominated by severe neurological impairment, developmental regression, spasticity, cavitating leukoencephalopathy, anemia, and optic atrophy.[7] Feng et al. describe a Chinese girl with compound heterozygous GLRX5 mutations (c.151_153delAAG [p.K51del] and c.196C>T [p.Q66Ter]) who developed developmental regression, spasticity, bilateral cavitating leukoencephalopathy, anemia, and optic atrophy, along with elevated glycine levels and deficiency of mitochondrial respiratory chain complexes II+III in fibroblasts.[7] The authors note that “mutations in GLRX5 have been associated with the variant NKH in humans because of disorders in the biosynthesis of lipoyl-H,” implicating GLRX5’s role in Fe–S cluster provision to lipoate synthase (LIAS) and the glycine cleavage system.[7]

Although anemia is also present in GLRX5-related variant NKH, the overall phenotype is syndromic and early-onset, distinct from the non-syndromic adult-onset microcytic hypochromic anemia with liver iron overload described in SIDBA3.[4][7][13] For disease knowledge base purposes, it is crucial to differentiate “GLRX5-related autosomal recessive sideroblastic anemia (SIDBA3)” from “GLRX5-related variant non-ketotic hyperglycinemia,” even though they share a molecular basis in GLRX5 deficiency. Suggested HPO terms for variant NKH phenotypes include “Developmental regression,” “Spasticity,” “Leukoencephalopathy,” “Optic atrophy,” “Hyperglycinemia,” and “Combined mitochondrial respiratory chain complex II and III deficiency.”[7] These neurological and metabolic features are not part of the canonical SIDBA3 phenotype as currently defined but illustrate the pleiotropic consequences of severe GLRX5 dysfunction in different tissues and developmental contexts.[7][1]

4. Genetic and Molecular Information

4.1 GLRX5 Gene, Protein, and Molecular Function

GLRX5 (HGNC:20134) is a nuclear gene encoding glutaredoxin 5, a small mitochondrial protein that plays a pivotal role in Fe–S cluster biogenesis and iron homeostasis.[2][3][10] The GLRX5 gene is located on chromosome 14q32, and its product is targeted to the mitochondrial matrix, where it participates in the maturation and transfer of Fe–S clusters to recipient apoproteins.[3][10] Ye et al. demonstrated that GLRX5 is essential for Fe–S cluster biosynthesis in human cells; GLRX5-deficient cells showed impaired assembly of Fe–S clusters, decreased activity of Fe–S–dependent enzymes, and activation of iron regulatory pathways.[10] The Human Protein Atlas indicates that GLRX5 is expressed in a wide range of tissues, including bone marrow, liver, skeletal muscle, heart muscle, and various regions of the central nervous system, consistent with a broad housekeeping role in mitochondrial metabolism.[16] Despite this widespread expression, GLRX5 deficiency in humans appears to manifest clinically predominantly in red blood cells and, in some cases, in the central nervous system, suggesting tissue-specific thresholds or compensatory mechanisms.[10][14][7]

From a gene ontology perspective, GLRX5 is associated with biological processes such as “iron–sulfur cluster assembly,” “mitochondrial organization,” “cellular response to oxidative stress,” and “heme biosynthetic process,” reflecting its role in supplying Fe–S clusters to enzymes involved in these pathways.[10][1] At the molecular level, GLRX5 functions as a monothiol glutaredoxin, utilizing reduced glutathione to mediate redox reactions involved in cluster transfer and repair.[10] Its disruption leads to widespread impairment of Fe–S–dependent proteins, including mitochondrial aconitase, components of the respiratory chain, and enzymes of lipoic acid and heme synthesis.[10][1][7] In the context of sideroblastic anemia, the most relevant downstream targets are ALAS2 and ferrochelatase, whose activities are reduced in GLRX5-deficient erythroblasts, leading to defective heme production.[1][10]

4.2 Pathogenic Variant Types and Functional Consequences

The GLRX5 variants associated with sideroblastic anemia 3 fall predominantly into the class of loss-of-function mutations, including splice-site disruptions, nonsense mutations, frameshift insertions, and certain missense changes that abolish or severely impair GLRX5 function.[14][7][11][13] The c.294A>G splice-site mutation in intron 1 interferes with normal mRNA splicing, drastically reducing GLRX5 RNA levels and thus protein expression; this leads to impaired Fe–S cluster biogenesis, as evidenced by reduced aconitase and other Fe–S enzyme activities in patient cells.[14] Nonsense mutations such as c.196C>T (p.Q66Ter), described in a variant NKH patient, truncate the GLRX5 protein within its functional core, likely causing complete loss of function.[7] Frameshift mutations like c.82_83insGCGTGCGG (p.G28Gfs*25) likewise produce truncated, nonfunctional proteins.[7]

Missense variants such as p.K51del (an in-frame deletion) and p.Lys101Gln or p.Leu148Ser are more nuanced, potentially affecting protein stability, mitochondrial targeting, or specific interactions within the Fe–S assembly machinery.[7][13] Functional characterization of K51del in variant NKH suggests that even small alterations within the N-terminal region can destabilize GLRX5 and disrupt its ability to support Fe–S cluster formation.[7] Arias et al. reported two novel GLRX5 mutations in patients with sideroblastic anemia, likely representing additional loss-of-function alleles, although the precise functional data are not fully detailed in accessible summaries.[11][13] In all cases, the functional consequences converge on impaired Fe–S cluster assembly, abnormal IRP regulation, and defective heme synthesis in erythroblasts.[10][1][14]

ClinVar and other variant databases classify most GLRX5 mutations associated with sideroblastic anemia or variant NKH as pathogenic or likely pathogenic, consistent with ACMG/AMP guidelines for loss-of-function variants in genes where such mechanisms are established as disease-causing.[3][13] Allele frequencies in population databases such as gnomAD are extremely low, reflecting the rarity of both disease and pathogenic variants; many GLRX5 mutations associated with disease are absent or present only as singletons in these datasets.[4][13] All reported disease-causing GLRX5 variants are germline and inherited in an autosomal recessive fashion; no somatic GLRX5 mutations have been implicated in hematologic malignancies or acquired sideroblastic anemia.[3][14]

4.3 Modifier Genes, Epigenetics, and Chromosomal Abnormalities

To date, no specific modifier genes have been identified that consistently alter the severity or expression of GLRX5-related sideroblastic anemia, although the broader genetic context of iron metabolism and heme biosynthesis likely influences individual phenotypes.[3][11][14] For example, the erythroid-specific ALAS2 gene, whose mRNA contains an iron-responsive element in its 5′ untranslated region, is a critical downstream target of IRP1/IRP2 and may amplify the erythroid consequences of GLRX5 deficiency by being more sensitive to iron-regulatory perturbations than its ubiquitous counterpart ALAS1.[3][8][10] However, no documented cases combine GLRX5 and ALAS2 mutations, so direct gene–gene interactions remain hypothetical. Similarly, genes such as HSPA9 and HSCB, which encode other components of the mitochondrial Fe–S assembly system and can themselves cause hereditary sideroblastic anemia when mutated, highlight the interconnected nature of this pathway but have not been identified as modifiers of GLRX5-related disease.[3][13]

There is no evidence that epigenetic alterations, such as DNA methylation or histone modifications, directly contribute to the pathogenesis of SIDBA3 beyond their general roles in gene expression regulation.[10][1] GLRX5-related sideroblastic anemia has not been associated with chromosomal structural abnormalities such as deletions, duplications, translocations, or inversions; all reported cases involve point mutations or small indels at the sequence level.[3][14][11] Cytogenetic studies in the index patient and subsequent cases have not revealed consistent karyotypic anomalies, further supporting a monogenic etiology.[14][11] Thus, the genetic architecture of SIDBA3 is currently best described as a rare, autosomal recessive, single-gene disorder with loss-of-function GLRX5 variants as the primary causal factor and no known recurrent modifying loci or chromosomal abnormalities.

5. Environmental Information

5.1 Non-Genetic Contributors and Distinction from Acquired Sideroblastic Anemia

For GLRX5-related sideroblastic anemia (SIDBA3), no specific environmental, toxic, or infectious agents have been implicated as causal contributors; the disease is fundamentally genetic, arising from germline GLRX5 mutations.[3][4][13] This distinguishes SIDBA3 from secondary or acquired sideroblastic anemias, which can be caused by a variety of non-genetic factors such as chronic alcohol use, lead intoxication, copper deficiency, and exposure to certain drugs (e.g., isoniazid, linezolid, chloramphenicol) that directly or indirectly impair heme synthesis or mitochondrial function.[9] ICD-10 explicitly differentiates “Hereditary sideroblastic anaemia” (D64.0) from “Secondary sideroblastic anaemia due to disease” (D64.1) and “Secondary sideroblastic anaemia due to drugs and toxins” (D64.2), underscoring the importance of distinguishing genetic from environmental etiologies.[9]

In the reported GLRX5-deficient patients, there is no evidence that environmental exposures such as alcohol, toxins, or medications played a primary role in causing anemia; rather, these individuals developed anemia in the context of a lifelong genetic defect, with environmental factors mainly modulating the severity or complications of the disease.[14][11] This distinction is clinically relevant because management strategies differ: acquired sideroblastic anemia may improve with removal of the offending agent or nutritional supplementation, whereas hereditary forms like SIDBA3 require ongoing management of anemia and iron overload and cannot be corrected by environmental modification alone.[3][9][13] Nonetheless, awareness of environmental causes is important when constructing a differential diagnosis for sideroblastic anemia and when excluding secondary etiologies before pursuing genetic testing for rare hereditary forms.[9][3]

5.2 Lifestyle Factors and Iron Loading

While lifestyle factors such as diet, exercise, and alcohol consumption are not known to initiate GLRX5-related sideroblastic anemia, they can influence iron balance and organ health in affected individuals. Excessive dietary iron intake or non-indicated oral iron supplementation could exacerbate iron overload in patients with SIDBA3, although the contribution of dietary iron is generally minor compared to transfusional iron loading.[14][13] Conversely, adherence to a balanced diet without excessive iron and avoidance of iron-containing supplements unless clinically indicated are prudent supportive measures.[14][13] Alcohol intake, though not etiologically linked to GLRX5 mutations, can aggravate liver injury in the context of hepatic iron overload, and abstinence or moderation is advisable to minimize cumulative hepatotoxicity.[9][14]

Physical activity and weight management may influence the risk and course of type 2 diabetes, which has been noted as a complication in the GLRX5-related adult-onset sideroblastic anemia case described by Orphanet.[4] However, these lifestyle factors operate through general metabolic pathways and do not specifically target the underlying GLRX5 deficiency. No infectious agents have been implicated in triggering or worsening GLRX5-related sideroblastic anemia, and the disease is not contagious or zoonotic.[3][4][13] Overall, lifestyle and environmental factors in SIDBA3 primarily affect the severity of iron overload and its complications rather than the underlying hematologic defect.

5.3 Gene–Environment Interactions in Therapeutic Context

The most clear-cut gene–environment interaction in GLRX5-related sideroblastic anemia arises in the therapeutic domain, where manipulation of iron availability through transfusions and chelation directly interacts with the molecular consequences of GLRX5 deficiency. In the index patient, repeated blood transfusions exacerbated iron overload and worsened anemia, whereas iron chelation therapy partially improved hemoglobin levels by redistributing iron from overloaded mitochondria to the cytosol and relieving excessive IRP2 activity.[14] Camaschella et al. hypothesized that “iron chelation, redistributing iron to the cytosol, might relieve IRP2 excess, improving heme synthesis and anemia,” suggesting that pharmacologic modulation of iron distribution can counteract some of the downstream effects of GLRX5 mutations.[14]

This observation underscores that, in SIDBA3, environmental interventions (in the broad sense of exogenous drugs) can modify disease expression by targeting iron homeostasis, even though they do not correct the primary genetic defect.[10][14] It also highlights the need for careful management of transfusions, minimizing unnecessary iron loading while ensuring adequate oxygen-carrying capacity. Beyond iron-focused therapies, no other gene–environment interactions have been experimentally documented for GLRX5-related sideroblastic anemia, reflecting the rarity of the disease and the limited number of studied patients.[4][13][11] Future therapeutic strategies such as gene therapy or targeted molecular interventions would further blur the boundary between genetic and environmental influences by directly modifying the causal pathway, but these remain hypothetical at present.

6. Mechanism and Pathophysiology

6.1 Overview of Molecular Pathways Involved

The pathophysiology of GLRX5-related sideroblastic anemia centers on disruption of mitochondrial Fe–S cluster biogenesis, dysregulation of cellular iron homeostasis via IRP1 and IRP2, and consequent impairment of erythroid heme biosynthesis.[10][1][14] GLRX5 is part of a conserved mitochondrial Fe–S assembly machinery that synthesizes and transfers Fe–S clusters to a wide array of mitochondrial and cytosolic proteins, including enzymes of the tricarboxylic acid cycle, respiratory chain complexes, lipoic acid synthase, and heme biosynthetic enzymes.[10][1][7] In GLRX5-deficient cells, Ye et al. demonstrated that Fe–S cluster biosynthesis is impaired, leading to decreased activity of Fe–S–dependent enzymes and accumulation of apo-IRP1 in its RNA-binding form rather than its Fe–S–containing aconitase form.[10][12] As a result, IRP1 IRE-binding activity is activated, and IRP2 levels increase, reflecting a cellular state of perceived cytosolic iron depletion even as mitochondrial iron accumulates.[10][12][14]

These changes in IRP1/IRP2 activity profoundly affect the translation and stability of mRNAs containing iron-responsive elements (IREs) in their untranslated regions, notably ALAS2 and transferrin receptor 1 (TfR1), among others.[10][14] In erythroid cells, ALAS2 is the first and rate-limiting enzyme in the heme biosynthetic pathway, converting glycine and succinyl-CoA to delta-aminolevulinic acid in mitochondria; its mRNA contains a 5′ IRE that is subject to translational repression when IRPs are active.[3][8][10] Transferrin receptor mRNA contains multiple 3′ IREs that are stabilized by IRP binding, increasing iron uptake.[14] Thus, GLRX5 deficiency creates a paradoxical state in which iron uptake is enhanced but heme synthesis is suppressed, leading to mitochondrial iron overload, cytosolic iron depletion, and impaired hemoglobin production.[10][14] This molecular cascade underlies the clinical phenotype of sideroblastic anemia with iron overload.

6.2 GLRX5, Fe–S Cluster Assembly, and IRP Regulation

At the cellular level, GLRX5 functions as a monothiol glutaredoxin that receives Fe–S clusters from scaffold proteins and participates in their transfer to target apoproteins, including IRP1.[10][1] In its Fe–S–bound form, IRP1 acts as cytosolic aconitase, whereas in its Fe–S–free form, IRP1 serves as an iron regulatory protein that binds IREs in mRNAs.[10][12] Ye et al. showed that in GLRX5-deficient cells, IRP1 fails to assemble its Fe–S cluster and is locked in its IRE-binding state, while IRP2, which is normally degraded in iron-replete conditions, becomes stabilized due to altered iron sensing.[10][12] The consequences are increased IRP-mediated repression of 5′ IRE–containing mRNAs such as ALAS2 and decreased degradation of 3′ IRE–containing mRNAs such as TfR1, shifting the balance toward reduced heme synthesis and increased iron uptake.[10][14]

In zebrafish, the shiraz mutant, which lacks functional glutaredoxin 5, exhibits severe anemia and embryonic lethality due to insufficient biogenesis of mitochondrial Fe–S clusters and deregulated IRP1 activity.[14] As summarized by Camaschella et al., “The zebrafish mutant shiraz has severe anemia and is embryonically lethal because of glutaredoxin 5 deletion, insufficient biogenesis of mitochondrial iron-sulfur (Fe/S) clusters, and deregulated iron-regulatory protein 1 (IRP1) activity. This leads to stabilization of transferrin receptor 1 (TfR) RNA, repression of ferritin, and ALA-synthase 2 (ALAS2) translation with impaired heme synthesis.”[14] The human GLRX5-deficient patient shows analogous biochemical changes: low aconitase and H-ferritin levels, high TfR1 levels, and increased IRP1 binding, all compatible with increased IRP activity and iron misdistribution.[14] These observations firmly link GLRX5 to Fe–S cluster assembly and IRP regulation, placing it at the upstream end of the pathogenic cascade in SIDBA3.

Suggested GO biological process terms relevant to this mechanism include “iron–sulfur cluster assembly,” “iron homeostasis,” “regulation of translation,” “erythrocyte differentiation,” and “heme biosynthetic process.” At the level of cellular components, mitochondria (GO:0005739) and cytosol (GO:0005829) are central compartments, reflecting the subcellular localization of GLRX5 and IRP1/IRP2.[10][1][14] The involved cell types are predominantly erythroblasts and developing red blood cells (CL:0000565 and CL:0000232), which bear the brunt of heme synthesis impairment.[10][14]

6.3 Impairment of Heme Biosynthesis: ALAS2 and Ferrochelatase

Heme biosynthesis in erythroid cells involves a series of mitochondrial and cytosolic enzymatic steps, beginning with delta-aminolevulinic acid synthesis by ALAS2 and culminating in iron insertion into protoporphyrin IX by ferrochelatase.[3][8][10] GLRX5 deficiency impacts this pathway at multiple points. First, IRP-mediated repression of ALAS2 translation reduces the production of delta-aminolevulinic acid, limiting flux through the entire pathway.[10][14] Ye et al. showed that GLRX5-deficient human erythroblasts had markedly decreased ALAS2 protein and activity, correlating with reduced heme synthesis.[10] Second, Fe–S clusters are required for proper function of ferrochelatase, which contains an essential [Fe–S] cluster; GLRX5 deficiency impairs Fe–S cluster provision to ferrochelatase, reducing its activity and further diminishing heme production.[1][10]

The ScienceDirect article “GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase in human congenital sideroblastic anemia” reinforces this dual impact, concluding that “GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase activities and … demonstrate the key role of GLRX5 in modulating ALAS2 and ferrochelatase activities and in maintaining mitochondrial function.”[1] The combined effect of decreased ALAS2 and ferrochelatase activities is a sharp reduction in heme synthesis, particularly in erythroid precursors where ALAS2 is the dominant isoform and where high heme production is required for hemoglobin assembly.[3][8][10] This explains why GLRX5 deficiency manifests primarily as anemia, despite the gene’s ubiquitous expression: erythroblasts are uniquely sensitive to perturbations in ALAS2 and ferrochelatase activity due to their high heme demands and reliance on Fe–S–dependent regulatory mechanisms.[10][14]

6.4 Iron Misdistribution and Mitochondrial Dysfunction

A hallmark of GLRX5-related sideroblastic anemia is the misdistribution of iron between mitochondria and cytosol, leading to mitochondrial iron overload and relative cytosolic iron depletion.[10][12][14] Ye et al. reported that in GLRX5-deficient cells, mitochondrial iron content increased while cytosolic iron levels decreased, as evidenced by activation of IRP1 IRE-binding and increased IRP2 protein levels.[10] This pattern reflects enhanced iron uptake via TfR1 (due to IRP stabilization of TfR1 mRNA) and reduced iron storage in ferritin (due to IRP repression of ferritin translation), funneling iron into mitochondria where it accumulates in the absence of effective incorporation into heme.[10][14] In erythroblasts, this mitochondrial iron overload manifests microscopically as ringed sideroblasts, with iron deposits in perinuclear mitochondria.[9][14]

Mitochondrial dysfunction in GLRX5-deficient cells extends beyond iron overload; Fe–S–dependent enzymes of the respiratory chain are impaired, as documented in variant NKH patients who show decreased activities of mitochondrial respiratory chain complexes II+III in fibroblasts.[7] Feng et al. noted that their GLRX5-mutant patient had deficiency of respiratory chain enzymes, representing “the first report” of such mitochondrial dysfunction in a GLRX5 mutation context.[7] In zebrafish shiraz mutants, GLRX5 deletion leads to severe anemia and early lethality, indicating that mitochondrial dysfunction in this context is incompatible with normal vertebrate development.[14][1] Thus, GLRX5 deficiency disrupts both iron handling and mitochondrial bioenergetics, contributing to the pathophysiology of sideroblastic anemia and, in more severe cases, to systemic metabolic disease.

6.5 Distinguishing Hematologic and Neurological Mechanisms

While the core mechanism of GLRX5 deficiency—disrupted Fe–S cluster biogenesis—underlies both sideroblastic anemia and variant NKH, the downstream pathways and affected cell types differ, leading to distinct clinical phenotypes. In SIDBA3, the primary site of pathology is the erythroid lineage, where ALAS2 and ferrochelatase impairment and iron misdistribution lead to anemia and iron overload.[10][14][1] The relevant GO and CL terms here emphasize “erythrocyte differentiation,” “heme biosynthetic process,” “iron homeostasis,” and “erythroblast” cell types.[10][14] In contrast, in GLRX5-related variant NKH, the dominant mechanisms involve impaired lipoate synthesis and glycine cleavage system dysfunction, as LIAS (lipoate synthase) is Fe–S–dependent and requires proper Fe–S cluster assembly.[7] The glycine cleavage system plays a central role in glycine catabolism in the brain and other tissues, and its dysfunction leads to elevated glycine, neurotoxicity, and white matter damage.[7]

Feng et al. note that “mutations in LIAS, BOLA3 and the novel gene GLRX5 can cause variant NKH,” and that GLRX5 mutations cause NKH “because of disorders in the biosynthesis of lipoyl-H.”[7] Their GLRX5-mutant patient exhibited developmental regression, spasticity, cavitating leukoencephalopathy, and optic atrophy, indicating widespread CNS involvement.[7] Thus, although GLRX5 deficiency underlies both SIDBA3 and variant NKH, the causal chain from initial molecular defect to clinical manifestation diverges: in erythroid cells, it proceeds via ALAS2 and ferrochelatase to anemia; in neural tissues, it proceeds via LIAS and the glycine cleavage system to neurodegeneration and metabolic encephalopathy.[7][10][1] This distinction underscores the importance of cell type–specific pathways and thresholds in determining the phenotype of systemic Fe–S cluster assembly defects.

6.6 Upstream and Downstream Mechanistic Hierarchy

From a mechanistic standpoint, GLRX5 deficiency can be conceptualized as an upstream defect in the Fe–S cluster assembly pathway that triggers downstream disturbances in iron regulation, heme biosynthesis, and mitochondrial function. At the upstream level, loss-of-function GLRX5 variants impair Fe–S cluster assembly, affecting multiple Fe–S–dependent proteins and sensing mechanisms.[10][1][14] The next level involves dysregulation of IRP1/IRP2 and consequent changes in IRE-containing mRNAs, including ALAS2, TfR1, and ferritin.[10][12][14] These alterations, in turn, influence iron uptake, storage, and utilization, leading to mitochondrial iron overload and cytosolic iron depletion.[10][14] Downstream of these events, heme biosynthesis is suppressed, particularly in erythroid cells, due to reduced ALAS2 translation and ferrochelatase activity, culminating in anemia and ring sideroblast formation.[1][10][14]

Further downstream, chronic ineffective erythropoiesis and transfusional therapy result in systemic iron overload, causing organ-specific damage, especially in the liver and endocrine pancreas, manifesting as hepatic iron overload and diabetes.[4][13][14] In variant NKH, additional downstream pathways include impaired lipoate synthesis and glycine catabolism, leading to elevated glycine and neurotoxicity.[7] This hierarchical chain—from GLRX5 mutation to Fe–S cluster deficiency, IRP dysregulation, iron misdistribution, heme synthesis impairment, anemia, and iron overload—provides a coherent framework for understanding SIDBA3 pathophysiology and for identifying potential intervention points, such as modulating iron distribution or restoring Fe–S cluster assembly.[10][14][1]

7. Anatomical Structures Affected

7.1 Organ-Level Involvement: Bone Marrow, Blood, and Liver

At the organ level, GLRX5-related sideroblastic anemia primarily affects the bone marrow and blood, with secondary involvement of the liver and endocrine organs due to iron overload. The bone marrow is the site of erythropoiesis, and in SIDBA3, it is characterized by erythroid hyperplasia and the presence of ringed sideroblasts, reflecting ineffective maturation and mitochondrial iron accumulation in erythroblasts.[14][9] The resultant anemia is manifested in the peripheral blood as microcytic hypochromic red blood cells, with reduced hemoglobin and characteristic red cell indices.[4][13][14] From an anatomical ontology perspective, relevant UBERON terms include “bone marrow,” “blood,” and “spleen,” the latter sometimes involved in extramedullary erythropoiesis or secondary changes.[4][10][14]

The liver is a major site of iron deposition in GLRX5-related sideroblastic anemia, as highlighted by Orphanet’s description of “liver iron overload” in the adult-onset GLRX5-deficient patient.[4] Chronic iron accumulation in the liver can lead to hepatomegaly, fibrosis, cirrhosis, and functional impairment, although detailed liver histology has not been extensively reported for SIDBA3.[14][4] Endocrine organs, particularly the pancreas, can also be affected by iron deposition, contributing to the development of type 2 diabetes noted in the Orphanet case.[4][13] Cardiac iron overload, a common complication in other sideroblastic anemias and transfusion-dependent anemias, has not been specifically documented in GLRX5-related cases but is a potential concern.[9][14] Thus, the primary body systems involved in SIDBA3 are the hematologic system (bone marrow, blood), digestive system (liver), and endocrine/metabolic system (pancreas, glucose regulation).

7.2 Tissue and Cell-Level Involvement

At the tissue level, the most affected tissues are hematopoietic tissue (bone marrow), hepatic parenchyma, and, in variant NKH, neural tissue (white matter of the brain).[4][7][14] Within bone marrow, the critical cell populations are erythroblasts and other stages of the erythroid lineage, which show iron-laden mitochondria and ineffective maturation.[14][10] From a Cell Ontology perspective, relevant terms include “erythroblast,” “proerythroblast,” and “erythrocyte,” all of which are involved in the pathogenesis of sideroblastic anemia.[10][14] Hepatic parenchymal cells, particularly hepatocytes, accumulate iron in SIDBA3, leading to hepatic iron overload; Kupffer cells and other stromal cells may also be involved in iron handling.[4][14] In variant NKH, oligodendrocytes and other glial cells in the white matter are affected, as evidenced by cavitating leukoencephalopathy.[7]

Ye et al.’s work in human erythroblasts confirms that GLRX5 deficiency has cell-specific effects in erythroid progenitors, where heme synthesis and iron distribution are tightly regulated to support hemoglobin production.[10][1] They observed that GLRX5-deficient erythroblasts had impaired heme synthesis and mitochondrial iron overload, indicating that these cells are particularly vulnerable to GLRX5 loss.[10] The Human Protein Atlas shows GLRX5 expression in many tissues, including bone marrow, liver, heart, skeletal muscle, and various brain regions, but clinical manifestations in SIDBA3 are largely confined to erythroid and hepatic tissues.[16][10][14] This pattern suggests that other tissues may compensate for GLRX5 deficiency or have lower dependence on Fe–S–mediated regulation of heme synthesis.

7.3 Subcellular Localization and Compartmental Involvement

At the subcellular level, GLRX5-related sideroblastic anemia prominently involves mitochondria, where GLRX5 resides and where Fe–S cluster assembly and heme biosynthesis occur.[10][1][14] Mitochondrial iron overload in erythroblasts leads to the characteristic ring sideroblast morphology, with iron-laden mitochondria encircling the nucleus.[9][14] Cytosolic compartments are also involved, as IRP1 and IRP2 operate in the cytosol and respond to changes in Fe–S cluster status and cytosolic iron levels.[10][12] The nucleus is indirectly affected through changes in gene expression driven by iron-regulated transcription factors and possibly by oxidative stress, although these aspects have not been deeply explored in SIDBA3.[10][1]

From a Gene Ontology cellular component perspective, relevant terms include “mitochondrion,” “mitochondrial matrix,” “cytosol,” and “nucleus,” reflecting the multi-compartmental nature of Fe–S cluster–dependent pathways.[10][1][14] In variant NKH, mitochondrial dysfunction in central nervous system cells contributes to white matter damage, implicating similar subcellular compartments in neural tissue.[7] However, in SIDBA3, the critical subcellular events occur in erythroblast mitochondria and cytosol, leading to localized iron overload and systemic anemia. The involvement of the endoplasmic reticulum and lysosomes, while potentially relevant for iron transport and degradation of ferritin, has not been specifically documented in GLRX5-related sideroblastic anemia.[10][14]

8. Temporal Development

8.1 Age of Onset and Pattern of Onset

GLRX5-related sideroblastic anemia 3 is characterized by adult onset of anemia, typically in mid-adulthood, as highlighted by Orphanet’s description of “adult onset microcytic hypochromic anemia” and MalaCards’ summary that “sideroblastic anemia-3 is an autosomal recessive hematologic disorder characterized by onset of anemia in adulthood.”[4][13] The index patient described by Camaschella et al. was a middle-aged man, and anemia had been present for many years before genetic diagnosis, suggesting an insidious onset and gradual progression.[14] Orphanet notes that the reported GLRX5-related adult-onset autosomal recessive sideroblastic anemia has a “mid-adulthood” onset, with point prevalence estimated at <1 per 1,000,000 worldwide.[4][13]

In contrast, GLRX5-related variant NKH presents in infancy or early childhood, with onset ages reported at around 2.5 to 7 years in Lebanese girls and 2.5 years in a Chinese boy, as summarized by Feng et al.[7] Their Chinese girl developed symptoms in early childhood, including developmental regression and spasticity, consistent with a pediatric onset of neurological disease.[7] Thus, the age of onset for GLRX5-associated conditions is phenotype-specific: adult-onset for SIDBA3, pediatric-onset for variant NKH. The pattern of onset in SIDBA3 is chronic and insidious, with anemia gradually becoming clinically apparent, whereas in variant NKH it is more acute or subacute, with neurological symptoms emerging relatively rapidly.[4][7][14]

8.2 Disease Progression, Course, and Duration

The progression of GLRX5-related sideroblastic anemia appears to be slowly progressive over many years, with anemia and iron overload worsening over time, particularly if not managed with iron chelation and transfusion optimization.[14][4][13] In the index adult case, anemia and iron overload had developed over decades, leading to significant hepatic iron deposition and type 2 diabetes by the time of diagnosis.[14] MalaCards notes that SIDBA3 is characterized by anemia in adulthood and systemic iron overload, implying a chronic course rather than episodic or relapsing-remitting patterns.[13] With appropriate management, including iron chelation and careful transfusion use, the anemia can be partially ameliorated, and iron-related complications can be mitigated, but the underlying genetic defect persists, making SIDBA3 a lifelong condition.[14][13]

Variant NKH due to GLRX5 mutations follows a more aggressive course, with rapid neurological deterioration, respiratory failure, and early death reported in some cases.[7] Feng et al. describe that their GLRX5-mutant NKH patient died of respiratory failure, and note that previous GLRX5-related NKH cases involved severe neurological morbidity.[7] In this phenotype, disease duration may span only a few years, with limited potential for recovery due to extensive CNS damage.[7] Thus, GLRX5-associated diseases display highly variable progression depending on the affected pathways and tissues: chronic, slowly progressive anemia and iron overload in SIDBA3, versus rapidly progressive neurodegenerative disease in variant NKH.[4][7][14]

8.3 Remission Patterns and Critical Periods

Spontaneous remission has not been reported in GLRX5-related sideroblastic anemia; the disease course is chronic and persistent due to the underlying genetic defect.[4][13][14] Treatment-induced improvement is possible, particularly with iron chelation, which can redistribute iron, relieve IRP-mediated repression, and partially restore heme synthesis, leading to better hemoglobin levels and reduced organ damage.[14][13] However, this represents partial control rather than true remission, as anemia and iron dysregulation remain and require ongoing management.[14][13] Critical periods of vulnerability in SIDBA3 include the years of accumulating iron overload, during which unchecked iron deposition can cause irreversible organ damage, emphasizing the importance of early recognition and intervention.[14][4]

In GLRX5-related variant NKH, critical periods include early childhood, when neurodevelopmental processes are underway and mitochondrial dysfunction and glycine toxicity can cause irreversible white matter damage.[7] Early diagnosis and supportive care may mitigate some complications, but no curative therapies are currently available, and the disease often progresses despite intervention.[7] From a developmental biology perspective, the difference in critical periods and remission patterns between SIDBA3 and variant NKH highlights how the same gene defect can have distinct temporal dynamics depending on the tissues and developmental windows involved.[7][10][1]

9. Inheritance and Population Characteristics

9.1 Inheritance Pattern, Penetrance, and Expressivity

Sideroblastic anemia 3 due to GLRX5 is inherited in an autosomal recessive manner, as indicated by OMIM, Orphanet, MalaCards, and PanelApp submissions.[2][3][4][13] Biallelic pathogenic GLRX5 variants are required to manifest the disease; heterozygous carriers are typically asymptomatic or may have subtle laboratory abnormalities but do not develop overt sideroblastic anemia.[14][11][13] The adult-onset case described by Camaschella et al. involved a homozygous splice-site mutation in GLRX5, and Arias et al. report patients with biallelic GLRX5 mutations causing sideroblastic anemia.[14][11][13] Orphanet classifies adult-onset autosomal recessive sideroblastic anemia due to GLRX5 as non-syndromic and autosomal recessive.[4]

Penetrance for biallelic GLRX5 loss-of-function mutations causing SIDBA3 appears to be high, given that all reported individuals with such mutations and sufficient follow-up have developed anemia and iron overload.[14][11][13] Age-dependent penetrance is likely, as anemia manifests in adulthood in SIDBA3, suggesting that younger individuals with biallelic mutations may be asymptomatic until heme synthesis demands and iron accumulation reach critical thresholds.[4][14] Expressivity may be variable, with differences in severity of anemia, degree of iron overload, and organ involvement among patients, although the small number of reported cases limits firm conclusions.[11][13][14] No evidence of genetic anticipation or germline mosaicism has been reported for GLRX5-related sideroblastic anemia.[3][14]

9.2 Epidemiology, Prevalence, and Demographics

GLRX5-related sideroblastic anemia is extraordinarily rare. Orphanet estimates the point prevalence of adult-onset autosomal recessive sideroblastic anemia due to GLRX5 at <1 per 1,000,000 worldwide.[4][13] MalaCards similarly lists a point prevalence of <1/1,000,000 and notes that “two unrelated men have been reported” with adult-onset sideroblastic anemia due to GLRX5 splice defects, as of its last curation.[13] The Blood 2007 case and subsequent reports likely account for these initial male cases.[14][11][13] A more recent report by Arias et al. adds additional patients, but the total number remains extremely low, likely fewer than ten worldwide.[11][13]

No particular ethnic or geographic predilection has been firmly established for SIDBA3, although individual cases have been reported from Europe and other regions.[14][11][13] Variant NKH due to GLRX5 has been reported in Lebanese and Chinese families, indicating that GLRX5 mutations causing neurological phenotypes are also distributed across diverse populations.[7] Sex ratio in SIDBA3 appears roughly balanced based on the limited data, with both male and female GLRX5 mutation carriers reported, although the earliest well-characterized adult-onset cases were male.[14][13] Overall, the extreme rarity of GLRX5-related sideroblastic anemia precludes robust epidemiological analysis; it is best classified as an ultra-rare autosomal recessive hematologic disease with global distribution at very low frequency.[4][13][14]

9.3 Carrier Frequency, Consanguinity, and Founder Effects

Carrier frequency for pathogenic GLRX5 variants is presumed to be extremely low, consistent with the rarity of documented cases and the scarcity of such variants in population databases.[4][13] No large-scale carrier screening studies have been performed for GLRX5, and gnomAD or similar databases show only sporadic, low-frequency variants, many of which are of uncertain significance.[13] Consanguinity may increase the likelihood of homozygous GLRX5 mutations, as in other autosomal recessive disorders, but specific consanguineous pedigrees have not been extensively reported for SIDBA3.[3][14] In variant NKH, some families may exhibit consanguinity or endogamous patterns, particularly in regions where such practices are common, but detailed genealogical data are limited.[7]

No founder effects have been conclusively demonstrated for GLRX5-related sideroblastic anemia, although the recurrent use of c.151_153delAAG (p.K51del) in Lebanese NKH cases suggests a possible founder mutation in that population.[7] For SIDBA3, the c.294A>G splice-site mutation has been described in at least one index patient without clear evidence of a broader founder effect.[14] Given the ultra-rare nature of SIDBA3, any founder mutations would likely be confined to small, geographically or culturally isolated populations and may not be easily detectable in global datasets.[4][13][14]

10. Diagnostics

10.1 Clinical and Laboratory Evaluation

Diagnosis of GLRX5-related sideroblastic anemia begins with recognition of a characteristic hematologic profile: microcytic hypochromic anemia, elevated serum iron and transferrin saturation, high ferritin, and evidence of iron overload, in the absence of more common causes such as thalassemia, chronic disease, or nutritional deficiencies.[4][9][13] Routine laboratory evaluation includes complete blood count (CBC) with red cell indices, serum iron studies (serum iron, transferrin saturation, ferritin), and reticulocyte count, which may show inappropriately low reticulocytes given the anemia, indicating ineffective erythropoiesis.[9][14] Iron studies in GLRX5-related sideroblastic anemia typically reveal elevated serum iron and transferrin saturation, reflecting increased iron availability, and high ferritin, indicating iron overload.[14][13]

Bone marrow examination is essential for confirming sideroblastic anemia. In SIDBA3, bone marrow aspirate and biopsy reveal erythroid hyperplasia and ringed sideroblasts, albeit sometimes in lower numbers than in other forms of sideroblastic anemia.[14][9] The presence of ring sideroblasts—erythroblasts with perinuclear iron-laden mitochondria—is pathognomonic of sideroblastic anemia and is often documented using Prussian blue staining for iron.[9][14] Additional laboratory tests may include liver function tests to assess hepatic involvement and endocrine evaluations (e.g., fasting glucose, HbA1c) to detect diabetes.[4][13][14] The combination of microcytic hypochromic anemia, ring sideroblasts, systemic iron overload, and lack of response to pyridoxine supplementation strongly suggests hereditary sideroblastic anemia, prompting genetic evaluation.[3][8][13]

10.2 Genetic Testing and Molecular Diagnosis

Genetic testing is central to establishing a definitive diagnosis of GLRX5-related sideroblastic anemia. The NCBI Genetic Testing Registry lists “Adult-onset autosomal recessive sideroblastic anemia” due to GLRX5 as a condition for which genetic tests are available, typically involving sequence analysis of the GLRX5 gene.[6] Genomics England’s PanelApp includes GLRX5 on gene panels for sideroblastic anemia, with a designation of autosomal recessive inheritance and MONDO:0014804 as the associated disease term.[2] Single-gene sequencing of GLRX5 (via Sanger or next-generation sequencing) can identify pathogenic variants such as the c.294A>G splice-site mutation or novel missense and frameshift changes.[14][11][13] Whole exome sequencing (WES) or whole genome sequencing (WGS) may be particularly useful in undiagnosed cases of sideroblastic anemia where candidate gene testing has not revealed a cause, enabling discovery of rare GLRX5 variants alongside other known sideroblastic anemia genes (ALAS2, SLC25A38, HSPA9, HSCB).[3][11][13]

Gene panels designed for hereditary sideroblastic anemia typically include ALAS2, SLC25A38, GLRX5, HSPA9, HSCB, and sometimes additional iron and heme metabolism genes.[2][3][13] Chromosomal microarray (CMA), karyotyping, or FISH are not generally informative for GLRX5-related disease, as the causal variants are sequence-level mutations rather than gross chromosomal abnormalities.[3][14] Mitochondrial DNA testing is likewise not directly relevant, as GLRX5 is a nuclear gene encoding a mitochondrial protein.[10][3] Once a pathogenic GLRX5 variant is identified, segregation analysis in family members can confirm autosomal recessive inheritance, identify carriers, and inform genetic counseling.[2][6][14]

10.3 Imaging, Histopathology, and Differential Diagnosis

Imaging studies, particularly MRI or CT of the liver, can document hepatic iron overload in GLRX5-related sideroblastic anemia, complementing biochemical iron studies.[4][14] Cardiac MRI may be considered in cases with long-standing iron overload to assess myocardial iron deposition, although specific data for SIDBA3 are lacking.[9][14] Histopathological examination of liver biopsy may reveal iron deposition in hepatocytes and Kupffer cells, consistent with secondary hemochromatosis, but such biopsies are not routinely required if non-invasive imaging and iron studies suffice.[4][14]

Differential diagnosis of sideroblastic anemia includes other hereditary forms, such as X-linked pyridoxine-responsive sideroblastic anemia due to ALAS2 mutations, autosomal recessive microcytic anemia with liver iron overload due to SLC25A38 mutations, and sideroblastic anemia due to HSPA9 or HSCB mutations.[3][8][15][13] Acquired sideroblastic anemia due to alcohol, lead, drugs, or myelodysplastic syndromes must also be excluded.[9] X-linked ALAS2-related disease often presents earlier and responds to pyridoxine, whereas GLRX5-related SIDBA3 is pyridoxine-refractory and has adult onset.[3][8][13] SLC25A38-related microcytic anemia with liver iron overload typically manifests in infancy or the neonatal period, in contrast to the adult onset of GLRX5-related disease.[15][3] HSPA9 and HSCB-related sideroblastic anemias may have distinct inheritance patterns (autosomal dominant for HSPA9) and additional features.[3][13] Thus, integration of clinical, laboratory, and genetic data is essential for precise diagnosis.

11. Outcome and Prognosis

11.1 Survival, Mortality, and Life Expectancy

Given the extremely small number of reported GLRX5-related sideroblastic anemia cases, detailed survival statistics and life expectancy estimates are not available. The adult-onset SIDBA3 phenotype appears compatible with long-term survival, as anemia and iron overload develop gradually and can be managed with appropriate therapy.[4][13][14] In the index patient, anemia and iron overload were significant but partially reversible with iron chelation, suggesting that with careful management, patients may live into middle and older age.[14] No SIDBA3-specific mortality rates or standardized survival curves have been published.[4][13]

In contrast, GLRX5-related variant NKH has a poor prognosis, with early death from respiratory failure or severe neurodegenerative complications reported in several cases.[7] Feng et al. note that their GLRX5-mutant NKH patient died of respiratory failure and that previous GLRX5-related NKH cases involved severe morbidity.[7] Thus, while GLRX5 deficiency can be associated with high mortality in the context of neurological disease, SIDBA3 itself appears to be a chronic, manageable condition with potential for prolonged survival, albeit with significant morbidity due to anemia and iron overload.[4][13][14]

11.2 Morbidity, Disability, and Quality-of-Life Outcomes

Morbidity in GLRX5-related sideroblastic anemia derives from chronic anemia, iron overload, and organ complications. Anemia contributes to fatigue, reduced physical capacity, and potential cardiovascular strain, affecting daily functioning and quality of life.[4][13][14] Iron overload can cause hepatic disease, diabetes, and possibly cardiac issues, each of which adds layers of morbidity.[4][14] Diabetes, in particular, can lead to microvascular and macrovascular complications that further impair function.[4][13] Although no formal quality-of-life assessments (e.g., SF-36 or EQ-5D) have been performed in SIDBA3 patients, extrapolation from other chronic anemias and iron overload disorders suggests substantial impact on physical and social functioning.[9][14]

In variant NKH, morbidity is dominated by severe neurological impairment, including developmental regression, spasticity, cavitating leukoencephalopathy, optic atrophy, and respiratory failure, leading to profound disability and dependence.[7] Feng et al. describe their GLRX5-mutant NKH patient as suffering from “developmental regression associated with spasticity, developmental delay, anemia and optic atrophy” and note that mitochondrial leukoencephalopathy was used to designate these disorders.[7] Such patients require intensive supportive care and have severely reduced quality of life.[7] For SIDBA3-specific knowledge bases, the focus should be on hematologic and iron-related morbidity, but awareness of GLRX5’s broader disease potential is important for comprehensive counseling.

11.3 Prognostic Factors and Treatment Response

Prognostic factors in GLRX5-related sideroblastic anemia likely include age at diagnosis, severity of anemia, degree of iron overload at presentation, responsiveness to iron chelation, and presence of organ complications such as cirrhosis or diabetes.[4][13][14] Early diagnosis and initiation of iron chelation can improve hemoglobin levels and reduce iron-related organ damage, suggesting that timely intervention is a favorable prognostic factor.[14][13] Camaschella et al. report that iron chelation partially reversed anemia in their GLRX5-deficient patient, highlighting treatment responsiveness as an important determinant of outcome.[14] Ongoing monitoring of ferritin, transferrin saturation, and organ function is essential for prognostic assessment.[9][14]

Genotype may also influence prognosis: GLRX5 mutations that severely abolish function (e.g., nonsense or frameshift variants) may predispose to more severe or syndromic phenotypes, including variant NKH, whereas splice-site or missense variants with partial residual function may manifest predominantly as hematologic disease.[7][14][11] However, the small number of cases and overlapping phenotypes make it difficult to draw firm genotype–phenotype correlations.[11][13][7] Overall, prognosis in SIDBA3 is determined by the balance between chronic anemia and iron overload, the effectiveness of supportive therapies, and the absence or presence of severe organ complications.

12. Treatment

12.1 Pharmacologic Management: Iron Chelation and Supportive Therapies

The mainstay of pharmacologic treatment for GLRX5-related sideroblastic anemia is iron chelation therapy, aimed at reducing systemic iron overload and redistributing iron to alleviate IRP2-mediated repression and improve heme synthesis.[14][13] Camaschella et al. report that iron chelation therapy partially reversed anemia in their GLRX5-deficient patient, hypothesizing that chelation redistributed iron from overloaded mitochondria to the cytosol, relieving IRP2 excess and improving heme synthesis.[14] MalaCards notes that “iron chelation therapy may be beneficial” in SIDBA3 and that anemia may be responsive to iron chelation treatment.[13] Common iron chelators used in sideroblastic anemia and other iron overload conditions include deferoxamine, deferasirox, and deferiprone, classified under NCIT terms such as “Iron chelation therapy” (NCIT:C49687).

Blood transfusions are often used to manage severe anemia, particularly at diagnosis or during acute decompensations, but must be carefully balanced against the risk of exacerbating iron overload.[9][14] In the GLRX5-deficient patient, anemia was worsened by blood transfusions, highlighting the need for judicious transfusion use.[14] Erythropoiesis-stimulating agents (ESAs) have not been systematically studied in SIDBA3 but may have limited effectiveness given the fundamental defect in heme synthesis.[9][10] Pyridoxine supplementation, which is effective in X-linked ALAS2-related sideroblastic anemia, is not helpful in GLRX5-related SIDBA3, as the defect lies upstream in Fe–S cluster assembly and IRP regulation, not in pyridoxine-dependent enzyme function.[4][8][13]

12.2 Advanced and Experimental Therapeutics

Advanced therapeutics such as gene therapy, cell therapy, and targeted molecular interventions for GLRX5-related sideroblastic anemia remain theoretical at present; no clinical trials specifically targeting GLRX5 deficiency have been reported.[4][13][10] In principle, gene therapy using viral vectors to deliver functional GLRX5 to hematopoietic stem cells could correct the Fe–S cluster defect in erythroid lineage cells and restore normal heme synthesis, analogous to emerging gene therapies for other monogenic hematologic disorders such as beta-thalassemia and sickle cell disease.[9][10] CRISPR-based gene editing to repair GLRX5 mutations in autologous stem cells is another potential strategy, but these approaches are still in preclinical or conceptual stages for SIDBA3.[10][1]

RNA-based therapies, such as antisense oligonucleotides to modulate splicing of GLRX5 or small interfering RNAs targeting negative regulators of Fe–S cluster assembly, are also conceivable but have not been explored specifically in GLRX5-related disease.[10][1] Targeted therapies aimed at modulating IRP1/IRP2 activity or enhancing ALAS2 translation might offer symptom relief, but again remain hypothetical.[10][14] In the context of variant NKH, therapies targeting the glycine cleavage system or lipoate synthesis have been discussed but not developed specifically for GLRX5-related cases.[7] Overall, advanced therapeutics for GLRX5 deficiency are an area of future research rather than current clinical practice.

12.3 Surgical and Supportive Treatments

No disease-specific surgical interventions have been described for GLRX5-related sideroblastic anemia. Standard surgical procedures for complications such as cholecystectomy (for gallstones), hepatic biopsy (for diagnostic purposes), or cardiac interventions (for iron-related cardiomyopathy) may be applied as needed, but these are not unique to SIDBA3.[9][14] Supportive care is essential, including management of anemia symptoms (e.g., fatigue), monitoring and treatment of iron-related organ damage (hepatic, endocrine, cardiac), and addressing comorbidities such as diabetes.[4][13][14]

Nutritional support, including avoidance of excess dietary iron and maintenance of overall health, can support general well-being but does not directly correct the underlying defect.[14][13] Rehabilitation services may be needed for variant NKH patients with neurological disability but are less relevant for non-syndromic SIDBA3.[7] Psychosocial support and patient education are important components of care, helping patients understand their condition, treatment options, and the importance of adherence to chelation and monitoring protocols.[4][13]

12.4 Treatment Algorithms and Personalized Medicine

Given the rarity of GLRX5-related sideroblastic anemia, no formal treatment guidelines or algorithms have been developed specifically for SIDBA3, but general principles for managing hereditary sideroblastic anemias can be applied. Initial evaluation should establish the type and severity of anemia, degree of iron overload, and presence of organ complications, followed by genetic confirmation of GLRX5 mutations.[3][9][13] Treatment strategies then focus on balancing transfusions (to manage anemia) with iron chelation (to manage overload), monitoring hemoglobin, ferritin, transferrin saturation, and organ function.[9][14] Personalized medicine approaches consider individual genotype, comorbidities, and response to therapy; for example, patients with severe GLRX5 mutations and rapid iron loading may require more intensive chelation and monitoring.[11][14][13]

Pharmacogenomic considerations, such as variation in genes affecting chelator metabolism or iron handling, have not been studied in SIDBA3 but may influence treatment response and toxicity in general.[9] As advanced therapies emerge, genotype-guided treatment may become more prominent, with specific interventions tailored to particular GLRX5 mutation types or functional deficits.[10][1] For now, however, personalized care in SIDBA3 is driven primarily by clinical parameters and individual response to iron-focused therapies.

13. Prevention

13.1 Primary, Secondary, and Tertiary Prevention

Primary prevention of GLRX5-related sideroblastic anemia is challenging, as the disease is monogenic and ultra-rare, arising from unpredictable germline mutations in most families. Population-level interventions such as vaccination or environmental risk factor modification have no direct role in preventing SIDBA3.[4][13][3] However, genetic counseling and carrier testing in families with known GLRX5 mutations can inform reproductive decisions and reduce recurrence risk, representing a form of targeted primary prevention.[2][6][14] Preimplantation genetic diagnosis (PGD) or prenatal testing are potential options for at-risk couples identified through family studies.[2][6][3]

Secondary prevention focuses on early detection and treatment to minimize complications. In SIDBA3, this involves recognizing unexplained microcytic hypochromic anemia with iron overload and pursuing genetic testing to identify GLRX5 mutations before severe organ damage occurs.[4][13][14] Early initiation of iron chelation and optimized transfusion practices can prevent or delay hepatic and endocrine complications, improving outcomes.[14][13] Screening for iron overload in patients with chronic anemia and transfusion history, using ferritin and imaging, can serve as a secondary prevention strategy for iron-related organ damage.[9][14]

Tertiary prevention aims to reduce morbidity and disability in patients already affected by SIDBA3. This includes rigorous management of diabetes and liver disease, monitoring for cardiac involvement, and providing supportive care to preserve functional capacity.[4][13][14] In variant NKH, tertiary prevention involves maximizing neurological function through rehabilitation and supportive therapies, although underlying disease progression may be difficult to halt.[7] Overall, prevention strategies in GLRX5-associated diseases focus on genetic counseling and early intervention rather than population-wide measures.

13.2 Genetic Counseling and Risk Stratification

Genetic counseling is a critical component of prevention in GLRX5-related sideroblastic anemia. Counselors can explain autosomal recessive inheritance patterns, carrier risks, and the implications of GLRX5 mutations for family planning.[2][6][14] At-risk couples (e.g., those in which both partners are carriers of a pathogenic GLRX5 variant) can consider options such as PGD, prenatal diagnosis, or adoption, depending on personal values and local regulations.[2][6][3] Siblings and extended family members of affected individuals may be offered carrier testing, enabling informed reproductive decisions and, in some cases, early detection of anemia or iron overload.[2][14]

Risk stratification within affected families can also guide clinical monitoring. For example, individuals with biallelic GLRX5 mutations may be monitored regularly for anemia and iron overload, even if asymptomatic, facilitating early intervention.[4][13][14] Those with single heterozygous mutations may not require intensive monitoring but may benefit from awareness of potential mild laboratory abnormalities.[14][11] Genetic counseling should also address the distinction between GLRX5-related SIDBA3 and variant NKH, clarifying that different mutations and developmental contexts can lead to different phenotypes.[7][1]

13.3 Public Health Considerations

Given the ultra-rare nature of GLRX5-related sideroblastic anemia, public health interventions such as population-wide screening or environmental regulation are not directly applicable. The disease is not infectious, not zoonotic, and not linked to specific environmental exposures at the population level.[3][4][13] Public health efforts in iron and anemia management focus instead on more prevalent conditions, such as iron deficiency anemia, thalassemia, and sickle cell disease.[9] Nonetheless, the existence of SIDBA3 highlights the need for specialized diagnostic pathways and registries for rare hematologic diseases, which can facilitate knowledge sharing, referral networks, and case aggregation.[4][13][3]

International collaborations and rare disease networks play a crucial role in improving recognition and management of conditions like GLRX5-related sideroblastic anemia, even if direct public health interventions are limited.[4][13] Data sharing across centers can help refine phenotypic descriptions, identify additional cases, and support research on mechanisms and therapies.[10][11][14] From a broader perspective, GLRX5-related disease contributes to public health understanding of iron metabolism and rare hereditary anemias.

14. Other Species and Natural Disease

14.1 GLRX5 Orthologs and Comparative Biology

GLRX5 has orthologs in multiple species, including zebrafish, yeast, and other vertebrates, reflecting its evolutionary conservation as a key player in Fe–S cluster assembly.[1][14][10] In zebrafish, the GLRX5 ortholog is mutated in the shiraz mutant, which exhibits severe anemia and embryonic lethality due to glutaredoxin 5 deletion and insufficient biogenesis of mitochondrial Fe–S clusters.[14] In yeast (Saccharomyces cerevisiae), Grx5 is a mitochondrial monothiol glutaredoxin required for Fe–S cluster assembly; its deficiency leads to widespread impairment of Fe–S–dependent proteins and sensitivity to oxidative stress, providing a model for GLRX5 function.[1] These orthologs underscore the conserved role of GLRX5/Grx5 in Fe–S cluster biology and iron homeostasis across species.

Comparative biology studies have shown that GLRX5 deficiency in zebrafish and yeast produces phenotypes analogous to human sideroblastic anemia, including anemia, Fe–S enzyme defects, and iron misdistribution, highlighting the shared mechanisms.[1][14][10] At the molecular level, GLRX5 orthologs participate in similar pathways, interacting with Fe–S scaffold proteins and redox partners to support cluster assembly and transfer.[10][1] This conservation supports the use of model organisms to study GLRX5-related disease.

14.2 Natural Animal Disease and Veterinary Relevance

No naturally occurring veterinary disease analogous to human GLRX5-related sideroblastic anemia has been widely reported in companion animals such as dogs or cats. However, Fe–S cluster assembly defects and iron metabolism disorders do occur in various species, and GLRX5 orthologs are present, suggesting that similar diseases could exist.[1][14] Online Mendelian Inheritance in Animals (OMIA) and veterinary databases have not yet catalogued GLRX5-related sideroblastic anemia in domestic animals, reflecting both the rarity of such mutations and the limited scope of genetic testing in veterinary practice.

Nonetheless, the zebrafish shiraz mutant represents a natural (spontaneous) model of GLRX5 deficiency in a vertebrate species, with severe anemia and embryonic lethality.[14] Camaschella et al. explicitly refer to the human GLRX5-deficient patient as “the human counterpart of zebrafish shiraz,” highlighting the cross-species similarity.[14] From a veterinary perspective, understanding GLRX5 function may inform general principles of iron metabolism disorders in animals, even if direct clinical applications are currently limited.

14.3 Transmission and Zoonotic Potential

GLRX5-related sideroblastic anemia is a hereditary, non-infectious disease with no zoonotic potential. It is caused by germline mutations and cannot be transmitted between individuals except via genetic inheritance.[3][14] There is no evidence of cross-species transmission or susceptibility, beyond the shared molecular mechanisms in orthologous genes.[1][14] Thus, GLRX5-related disease is of interest in comparative pathology and molecular biology but does not pose a zoonotic or public health threat.

15. Model Organisms

15.1 Zebrafish Shiraz Mutant as a Model of GLRX5 Deficiency

The zebrafish shiraz mutant is a key model organism for studying GLRX5 deficiency and its consequences for hematopoiesis.[14][1][10] Shiraz carries a deletion of glutaredoxin 5, leading to severe anemia and embryonic lethality due to insufficient biogenesis of mitochondrial Fe–S clusters and deregulated IRP1 activity.[14] As noted by Camaschella et al., “The zebrafish mutant shiraz has severe anemia and is embryonically lethal because of glutaredoxin 5 (GRLX5) deletion, insufficient biogenesis of mitochondrial iron-sulfur (Fe/S) clusters, and deregulated iron-regulatory protein 1 (IRP1) activity.”[14] This model reproduces many features of human GLRX5-related sideroblastic anemia, including impaired heme synthesis, iron misdistribution, and severe anemia, making it valuable for mechanistic studies.

Phenotype recapitulation in shiraz includes stabilization of TfR1 mRNA, repression of ferritin, decreased ALAS2 translation, and impaired heme synthesis, closely paralleling the human biochemical phenotype.[14][10] Limitations of the zebrafish model include its embryonic lethality, which restricts study of adult iron overload and organ complications, and species-specific differences in hematopoiesis.[14][1] Nonetheless, zebrafish provide a powerful system for genetic manipulation, imaging, and high-throughput screening, enabling exploration of GLRX5-related pathways and potential therapeutic interventions.[1][10]

15.2 Yeast Grx5 and Cellular Models

Yeast Grx5 knockout strains serve as another model for GLRX5 function, illustrating the role of mitochondrial monothiol glutaredoxins in Fe–S cluster assembly and iron homeostasis.[1] Deficiency of glutaredoxin 5 in yeast reveals that Fe–S clusters are required for mitochondrial and cytosolic enzymes and that their loss leads to widespread metabolic derangement.[1] These cellular models have been instrumental in defining the biochemical roles of GLRX5/Grx5 and in implicating Fe–S cluster defects in heme synthesis and iron regulation.[1][10]

Human cellular models, including GLRX5-deficient fibroblasts from patients and GLRX5 knockdown cells generated by RNA interference, complement organismal models by allowing detailed analysis of Fe–S clusters, IRP activity, iron distribution, and heme synthesis.[10][7] Ye et al. used such models to demonstrate impaired Fe–S cluster biosynthesis, activation of IRP1 IRE-binding, increased IRP2, cytosolic iron depletion, and mitochondrial iron overload in GLRX5-deficient human cells, providing direct mechanistic evidence relevant to human disease.[10][12] These models are particularly suited for in vitro screening of potential therapeutic compounds or genetic interventions.

15.3 Applications and Limitations of Model Systems

Model organisms and cellular systems have been indispensable in elucidating the pathophysiology of GLRX5-related sideroblastic anemia, but they also have limitations. Zebrafish and yeast provide insights into conserved mechanisms of Fe–S cluster assembly and iron regulation, but their hematopoietic systems and organ structures differ from humans, potentially limiting translational applicability.[1][14] Embryonic lethality in zebrafish shiraz mutants precludes study of chronic iron overload and adult organ pathology.[14] Yeast lacks erythrocytes and therefore cannot model anemia directly, though it can illustrate heme synthesis and Fe–S–dependent processes.[1]

Human cellular models bridge some of these gaps but lack the systemic context of an intact organism.[10][7] No specific mouse models of GLRX5-related sideroblastic anemia have been widely reported, though GLRX5 knockout mice would be expected to have severe Fe–S cluster defects.[1][10] As research advances, generation of conditional GLRX5 knockout mice targeting the erythroid lineage could provide a powerful model for SIDBA3, enabling study of anemia, iron overload, and organ complications in a mammalian system. For now, zebrafish shiraz, yeast Grx5 mutants, and human cell models collectively provide a robust platform for understanding GLRX5-related disease mechanisms and exploring potential therapies.

Conclusion

Sideroblastic anemia 3 (GLRX5-related autosomal recessive sideroblastic anemia) is a paradigmatic ultra-rare hereditary hematologic disorder that illuminates the critical role of mitochondrial Fe–S cluster biogenesis and iron regulatory pathways in erythroid heme synthesis. Clinically, SIDBA3 presents as adult-onset microcytic hypochromic anemia, bone marrow ringed sideroblasts, and systemic iron overload, often accompanied by hepatic iron deposition and metabolic complications such as type 2 diabetes.[4][13][14] It is caused by biallelic germline loss-of-function mutations in GLRX5, including splice-site, nonsense, frameshift, and certain missense variants that impair GLRX5 function and Fe–S cluster assembly.[14][7][11][13] Mechanistic studies in human cells, zebrafish, and yeast demonstrate that GLRX5 deficiency disrupts Fe–S cluster biogenesis, activates IRP1/IRP2, misdistributes iron between mitochondria and cytosol, and suppresses the erythroid heme biosynthetic enzymes ALAS2 and ferrochelatase, leading to defective heme production and iron-laden mitochondria in erythroblasts.[10][1][14]

Diagnostic evaluation of SIDBA3 involves recognition of characteristic hematologic and iron profiles, bone marrow demonstration of ring sideroblasts, and genetic confirmation of GLRX5 mutations via targeted sequencing or exome/genome analysis.[3][4][6][13] Differential diagnosis includes other hereditary sideroblastic anemias (ALAS2, SLC25A38, HSPA9, HSCB) and acquired sideroblastic anemia due to toxins or drugs, with GLRX5-related disease distinguished by adult onset, pyridoxine refractoriness, and Fe–S cluster involvement.[3][8][15][13] Treatment centers on careful management of anemia and iron overload, particularly through iron chelation therapy, which can redistribute iron and partially restore heme synthesis, and judicious transfusion use to avoid excessive iron loading.[14][13] Advanced therapeutics such as gene therapy remain theoretical but represent promising avenues for future research, given the monogenic nature of the disease.[10][1]

From a broader perspective, GLRX5-related disease exemplifies how rare genetic disorders can yield profound insights into fundamental physiology. The discovery of GLRX5 deficiency in zebrafish shiraz mutants and in human SIDBA3 patients revealed the essential role of Fe–S clusters in vertebrate heme synthesis and iron regulation, while GLRX5-related variant non-ketotic hyperglycinemia extended this understanding to CNS metabolism and mitochondrial function.[1][7][10][14] The conserved function of GLRX5 orthologs across species underscores the value of comparative biology and model organisms in elucidating disease mechanisms. Clinically, SIDBA3 underscores the importance of considering hereditary sideroblastic anemia in adults with unexplained microcytic hypochromic anemia and iron overload, and of integrating genetic testing into hematologic practice for rare anemia syndromes.[3][4][13][14]

As knowledge of GLRX5-related disorders expands through additional case reports, mechanistic studies, and potential therapeutic trials, disease knowledge bases will play a crucial role in organizing and disseminating this information. Ontology-based annotations—linking GLRX5 to HGNC and GO terms, SIDBA3 to MONDO and ICD codes, phenotypes to HPO terms, cell types to CL terms, and treatments to NCIT interventions—will facilitate computational integration and support precision medicine applications. Ultimately, while GLRX5-related sideroblastic anemia remains an ultra-rare disease, its study continues to enrich our understanding of iron, heme, and mitochondrial biology, with implications extending far beyond the small number of affected patients.[10][1][14][13]

Reference Validation

No PMID or DOI references were found in this report.